Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Commences Offer for Orchid Shares

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has launched its cash tender offer to acquire all of the outstanding common shares of Orchid Cellmark.

The firms signed the merger agreement earlier this month, under which LabCorp will pay $2.80 per share to acquire all outstanding shares of Orchid including options. The total value of the deal is around $85.4 million.

The companies said the deal strengthens LabCorp's presence and brand name in identity testing in the US and establishes a presence in identity testing in the UK.

Orchid Cellmark's board has approved the agreement and plan of merger and has recommended that shareholders vote in favor of the acquisition.

The tender offer is scheduled to expire at 5:00 p.m., New York City time, on May 17, unless it is extended.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.